These results will advance our understanding of the oncogenic role of HBXIP, and indicates its potential as a novel diagnostic biomarker in NSCLC and as a therapeutic target in combination with MAPK inhibitors in cancer treatment (Figure 6). Here, LAMTOR5 is linked to non-small cell lung carcinoma.